Please assess the completion status of the following clinical trial:

Trial Title: Intralesional Antimony for Bolivian Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Gender: Male or female~* Age: \>12 yrs of age~* Clinicla presentation: 1-2 ulcerative lesions, each \< 30 mm in largest diameter, and with a total lesion area \<900 mm2.~* Parasitological confirmation of the lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion.~EXCLUSION CRITERIA:~* Previous treatment for leishmaniasis: therapy with Sb, pentamidine, amphotericin B, miltefosine, imidazoles or allopurinol in the last 3 months~* Concomitant diseases by history that would be likely in the PI's opinion to interact, either positively or negatively, with IL Sb treatment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intralesional antimony (Type: EXPERIMENTAL): 3 intralesional injections of antimony at D1, D3 and D7
- Cryotherapy (Type: ACTIVE_COMPARATOR): Liquid nitrogen until freezing at DF1 and D14
- Topical cream (Type: PLACEBO_COMPARATOR): topical treatment 3 times a day during 21 days with an emollient cream

Based on this trial design, predict the completion outcome and termination type (if applicable).